Get the Stockscreener App
4.40
0.45%
-0.02
After Hours:
4.45
0.05
+1.14%
Bioage Labs Inc stock is traded at $4.40, with a volume of 77,526.
It is down -0.45% in the last 24 hours and up +6.54% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$4.42
Open:
$4.44
24h Volume:
77,526
Relative Volume:
0.31
Market Cap:
$157.74M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.38%
1M Performance:
+6.54%
6M Performance:
-4.14%
1Y Performance:
+0.00%
1-Day Range:
$4.38
$4.485
1-Week Range:
$4.34
$4.71
52-Week Range:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
1445A SOUTH 50TH STREET, RICHMOND
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.40 | 158.46M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
BioAge Labs Requests to Dismiss Class Action Filed by Investors - TradingView
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery - MSN
Price Channel Expanding on BioAge Labs Inc.’s ChartEntry Alert Based on Volume Spikes Detected - beatles.ru
Can BioAge Labs Inc. Bounce Back From Weekly LowWeekly Top Gainers Forecast Watchlist Released - metal.it
Will BioAge Labs Inc. Benefit From Sector TailwindsReal Time Stock Movement Analysis Indicates Breakout - metal.it
Should I hold or sell BioAge Labs Inc. stock in 2025Capitalize on proven investment strategies - jammulinksnews.com
Competitive Positioning of BioAge Labs Inc.: Is It Leading or LaggingLow Risk Entry Points - metal.it
What is BioAge Labs Inc. company’s growth strategyPhenomenal capital gains - jammulinksnews.com
How strong is BioAge Labs Inc. company’s balance sheetInvest confidently with data-backed picks - jammulinksnews.com
What catalysts could drive BioAge Labs Inc. stock higher in 2025Explosive wealth accumulation - jammulinksnews.com
How does BioAge Labs Inc. compare to its industry peersGet exclusive access to premium stock research - jammulinksnews.com
What are the latest earnings results for BioAge Labs Inc.Phenomenal capital gains - jammulinksnews.com
Is BioAge Labs Inc. a growth stock or a value stockRapidly expanding wealth - jammulinksnews.com
What analysts say about BioAge Labs Inc. stockOutstanding stock performance - Autocar Professional
Is BioAge Labs Inc. a good long term investmentOutperformance with explosive growth - PrintWeekIndia
What drives BioAge Labs Inc. stock pricePhenomenal capital appreciation - Autocar Professional
BioAge Labs Inc. Stock Analysis and ForecastPowerful growth strategies - jammulinksnews.com
BIOA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by BioAge Labs, Inc. - ACCESS Newswire
Is BioAge Labs (NASDAQ:BIOA) Weighed On By Its Debt Load? - simplywall.st
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):